Associate Director - Medical Science Liaison Eli Lilly
This poster showcases the results of the SURPASS-6 trial. In this trial, the addition of tirzepatide (TZP) to basal insulin glargine U100 for participants with long-standing type 2 diabetes (T2D) who were not meeting glycemic targets substantially improved HbA1c and body weight. The poster also includes evaluation of degrees of insulin dose reductions and the efficacy and safety of TZP based on residual insulin use at Week 52.
